As Congress debates partisan issues such as “Medicare for All” where private health insurance would be outlawed, troubling trends are emerging on healthcare provider consolidation that are driving up costs.

A retired pharma executive decides to tackle the daunting task of revamping the U.S. healthcare system.

What makes a successful merger? Here we look at the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases.

Growing a life sciences company will have continuous demands for funding. Wherever that money comes from, undertaking a commitment to PCAOB (Public Company Accounting Oversight Board) compliance will be valued by potential investors.

Are we better at bringing expensive new drugs to market than we are at embracing technology that reduces the cost and improves care delivery? Both options improve patient lives, but only one does so affordably.